For research use only. Not for therapeutic Use.
MIDD0301 (Cat No.: I040635) is an investigational small-molecule GABA<sub>A</sub> receptor modulator with anti-inflammatory and bronchodilatory properties, developed for the treatment of asthma and other respiratory diseases. Unlike traditional therapies, MIDD0301 targets GABA<sub>A</sub> receptors in the lungs, reducing inflammation and relaxing airway smooth muscle without central nervous system side effects. It offers a novel, non-steroidal approach to asthma management, potentially improving symptoms and reducing corticosteroid reliance. MIDD0301 is currently being evaluated in preclinical and early clinical studies for safety and efficacy.
| CAS Number | 2187489-08-1 |
| Synonyms | (4R)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid |
| Molecular Formula | C19H13BrFN3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H13BrFN3O2/c1-10-18-17(19(25)26)22-9-24(18)15-7-6-11(20)8-13(15)16(23-10)12-4-2-3-5-14(12)21/h2-10H,1H3,(H,25,26)/t10-/m1/s1 |
| InChIKey | OSBXEAZWQGBYFU-SNVBAGLBSA-N |
| SMILES | CC1C2=C(N=CN2C3=C(C=C(C=C3)Br)C(=N1)C4=CC=CC=C4F)C(=O)O |
| Reference | [1]. Yocum GT, et al. A novel GABAA receptor ligand MIDD0301 with limited blood-brain barrier penetration relaxes airway smooth muscle ex vivo and in vivo. Am J Physiol Lung Cell Mol Physiol. 2019 Feb 1;316(2):L385-L390. [2]. Zahn NM, et al. MIDD0301 – A first-in-class anti-inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression. Basic Clin Pharmacol Toxicol. 2019 Jul;125(1):75-84. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
